Buy Fasoracetam powder (110958-19-5)HPLC≥98% from Wisepowder

www.wisepowder.com

wise12@wisepowder.com

Buy Fasoracetam powder (110958-19-5)HPLC≼98% from Wisepowder 01

Overview

Fasoracetam powder is a research compound and member of the racetam family of nootropics, primarily known for their cognitive enhancing abilities. Fasoracetam is also an axiolytic and may be able to improve mood as well. This racetam works by affecting three receptors within the brain: acetylcholine, GABA, and glutamate, all three of which are involved in the creation and retention of memories. On top of that, it has the potential to become a full-blown drug fortreating ADHD as a non-stimulant.

1/5

www.wisepowder.com

wise12@wisepowder.com

02

Fasoracetam powder (110958-19-5) video

03

Fasoracetam powder Base Information

Name

Fasoracetam powder

CAS

110958-19-5

Purity

98%

Chemical name

(R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine

Synonyms

Fasoracetam; N-(5-Oxo-D-prolyl)piperidine; NS-105; NFC-1; LAM-105.

Molecular Formula

C10H16N2O2

Molecular Weight

196.25 g/mol

Melting Point

57 °C

InChI Key

GOWRRBABHQUJMX-MRVPVSSYSA-N

Form

Solid

Appearance

White powder

Half Life

1.5 hours

Solubility

Soluble in DMSO

Storage Condition

Store in dry, dark conditions at 0 - 4 °C for short-term (day/weeks), and - 20°C for long term storage.

Application

Agonist of all three metabotropic glutamate receptors (mGluRs) with potential antidepressant action, that has been used in clinical trials for vascular dementia and attention deficit disorder

Testing Document

Available

04

Fasoracetam powder General Description

Fasoracetam powder (also known as NS-105, LAM-105, and NFC-1) is a nootropic or smart drug that belongs to the racetam family of drugs. It was first developedin the early 1990s by the Japanese pharmaceutical company Nippon Shinyakuwith the intention of treating vascular dementia. The company spent over $200 million developing fasoracetam, however, the drug failed to make it past phase 3 clinical trials due to a lack of efficacy and was eventually abandoned.

In 2013, interest in fasoracetam was revived when a company called NeuroFi purchased the clinical data for the drug from Nippon Shinyaku. NeuroFix was later acquired by Aevi Genomic Medicine, which began clinical trials in 2016 in 2/5

www.wisepowder.com

wise12@wisepowder.com

adolescents with ADHD, autism, or anxiety, who have mutations in the glutamate receptor gene. Fasoracetam is currently in phase 2 clinical trials

05

Fasoracetam powder (110958-19-5) History

Fasoracetam powder was created in the 1990s by the Japanese pharmaceutical company Nippon Shinyaku as a possible treatment for vascular dementia.

Development was halted after disappointing clinical trials, but in 2013 the clinical data on fasoracetam (sometimes referred to in research literature as NS-105 or NFC-1) was purchased by the US-based firm NeuroFix, a subsidiary of Aevi Genomic Medicine.

In 2015, fasoracetam powder was accepted by the US Food and Drug Administration’s Investigational New Drug program, which grants the developers permission to start human clinical trials and ship the drug across state lines.

Clinical trials on fasoracetam started again in 2016, investigating the compound’s potential for treating Attention Deficit Hyperactivity Disorder (ADHD) in children who demonstrate a specific mutation of the glutamate receptor system. The trials suggested that fasoracetam has potential as a non-stimulant alternative to Adderall and other amphetamine derivatives for ADHD treatment.

A phase II proof-of-concept trial was planned for 2018 to investigate fasoracetam as an autism spectrum disorder (ASD) treatment.

Fasoracetam has not been officially approved for any use by the USFDA and is classified as a research chemical that is not intended for human use.

06

Fasoracetam (110958-19-5) Mechanism Of Action

Like all racetams, the mechanism of action of fasoracetam is not fully understood.

Research has shown that fasoracetam works by the following mechanisms: Fasoracetam increases the release of acetylcholine from the cerebral cortex.

Acetylcholine is a neurotransmitter in the brain is responsible for memory and learning. Fasoracetam also increases the uptake of choline, a nutrient needed to create acetylcholine throughout the brain.

Fasoracetam increases the number of receptors (in the cortex) for the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).

3/5

www.wisepowder.com

wise12@wisepowder.com

It also activates certain types of glutamate receptors (metabotropic glutamate receptors – mGluRs). Glutamate is the main excitatory neurotransmitter, and mGluRs have many functions throughout the brain [R, R].

07

Fasoracetam (110958-19-5) Application

1) May Prevent Memory Loss In rats, fasoracetam prevented memory problems caused by baclofen, a GABA-B receptor activator. It also reduced amnesia by increasing acetylcholine and reducing the effects of GABA-B activation.

2) May Reduce Symptoms of Depression Abnormal GABA levels are linked to certain brain disorders, including anxiety and depression. Fasoracetam reduced depressive symptoms in rats that were conditioned to feel helpless to avoid negative situations (learned helplessness)

08

Fasoracetam (110958-19-5) More Research

Fasoracetam powder is a research chemical of the racetam family. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia.

It is currently being studied for its potential use for attention deficithyperactivity disorder.

Scientists at Children’s Hospital of Philadelphia led by Hakon Hakonarson havestudied fasoracetam’s potential use in attention deficit hyperactivity disorder.

09

Fasoracetam (110958-19-5) Document Download

COA

10  

Fasoracetam (110958-19-5) Reference Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats. J Nutr. 2013 Sep;143(9):1406-13. doi: 10.3945/jn.113.177980. Epub 2013 Jul 17. PubMed PMID: 23864508; PubMed Central PMCID: PMC3743272.

4/5

www.wisepowder.com

 

wise12@wisepowder.com

LAM 105, NS 105. Drugs R D. 1999 Aug;2(2):135-6. PubMed PMID: 10820660.

Hirouchi M, Oka M, Itoh Y, Ukai Y, Kimura K. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105. Eur J Pharmacol. 2000 Jan 3;387(1):9-17. PubMed PMID: 1063315

5/5